Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences

Contemporary Clinical Trials

Volumn 43, Issue , 2015, Pages 60-62

  Moncrieff, Joanna ^a   Kirsch, Irving ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antidepressant efficacy; Clinical relevance of antidepressant effects; Effect size in depression; Hamilton rating scale for depression; Measurement of depression

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; MIRTAZAPINE; PAROXETINE; PLACEBO;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; PSYCHOPHARMACOTHERAPY; SYMPTOM; DEPRESSIVE DISORDER, MAJOR; INFORMATION PROCESSING; PLACEBO EFFECT; PROCEDURES; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ANTIDEPRESSIVE AGENTS; DATA COLLECTION; DEPRESSIVE DISORDER, MAJOR; HUMANS; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929379847     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.05.005     Document Type: Article

References (38)

1. Gotzsche P. Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare 2013, Radcliffe Publishing Ltd., London.
2. Antonuccio D.O., Danton W.G., DeNelsky G.Y., Greenberg R.P., Gordon J.S. Raising questions about antidepressants. Psychother. Psychosom. 1999, 68(1):3-14.
3. Moncrieff J., Kirsch I. Efficacy of antidepressants in adults. BMJ Jul 16 2005, 331(7509):155-157.
4. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry Feb 1960, 23:56-62.
5. Khin N.A., Chen Y.F., Yang Y., Yang P., Laughren T.P. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J. Clin. Psychiatry Apr 2011, 72(4):464-472.
6. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. Feb 2008, 5(2):e45.
7. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. Jan 17 2008, 358(3):252-260.
8. Gibbons R.D., Hur K., Brown C.H., Davis J.M., Mann J.J. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch. Gen. Psychiatry Jun 2012, 69(6):572-579.
9. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA Jan 6 2010, 303(1):47-53.
10. National Institute for Health and Clinical Excellence Depression: Management of Depression in Primary and Secondary Care. Clinical Practice Guideline Number 23 2004, National Institute for Clinical Excellence, London.
11. Turner E.H., Rosenthal R. Efficacy of antidepressants. BMJ Mar 8 2008, 336(7643):516-517.
12. National Institute for Health and Clinical Excellence Depression: Management of Depression in Primary and Secondary Care. Revised Clinical Practice Guideline Number 23 2009, National Institute for Health and Clinical Excellence, London.
13. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophr. Res. Nov 15 2005, 79(2-3):231-238.
14. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology Oct 2006, 31(10):2318-2325.
15. Lepping P., Sambhi R.S., Whittington R., Lane S., Poole R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br. J. Psychiatry May 2011, 198(5):341-345.
16. Leucht S., Fennema H., Engel R., Kaspers-Janssen M., Lepping P., Szegedi A. What does the HAMD mean?. J. Affect. Disord. Jun 2013, 148(2-3):243-248.
17. Guy W. The Clinical Global Impression Scale. ECDEU Assessment Manual for Psychopharmacology - Revised 1976, 218-222. US Department of Education, Health and Welfare, Rockville, MD.
18. Kadouri A., Corruble E., Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry 2007, 7:7.
19. Leon A.C., Shear M.K., Klerman G.L., Portera L., Rosenbaum J.F., Goldenberg I. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. J. Clin. Psychopharmacol. Oct 1993, 13(5):327-331.
20. Hedges D.W., Brown B.L., Shwalb D.A. A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum. Psychopharmacol. Jan 2009, 24(1):35-40.
21. Khan A., Leventhal R.M., Khan S.R., Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. Feb 2002, 22(1):40-45.
22. Berk M., Ng F., Dodd S., Callaly T., Campbell S., Bernardo M., et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J. Eval. Clin. Pract. Dec 2008, 14(6):979-983.
23. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int. Clin. Psychopharmacol. Dec 1995, 10(Suppl. 4):25-35.
24. Wade A., Crawford G.M., Angus M., Wilson R., Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int. Clin. Psychopharmacol. May 2003, 18(3):133-141.
25. Cohen J. Statistical Power Analysis for the Behavioural Sciences 1988, Lawrence Earlbaum Associates, Hillsdale, NJ. second edition.
26. OECD Health at a Glance 2013: OECD indicators 2013, OECD Publishing, Paris, ([updated 10-10-2014]; Available from: http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf?_ga=1.159836794.650866776.1405853144).
27. Gotzsche P. Psychiatric drugs are doing us more harm than good. The Guardian 2014.
28. Kirsch I., Moncrieff J. Clinical trials and the response rate illusion. Contemp. Clin. Trials 2007, 28:348-351.
29. Royston P., Altman D.G., Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat. Med. Jan 15 2006, 25(1):127-141.
30. MacCallum R.C., Zhang S., Preacher K.J., Rucker D.D. On the practice of dichotomization of quantitative variables. Psychol. Methods Mar 2002, 7(1):19-40.
31. Rutherford B.R., Sneed J.R., Roose S.P. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother. Psychosom. 2009, 78(3):172-181.
32. Sinyor M., Levitt A.J., Cheung A.H., Schaffer A., Kiss A., Dowlati Y., et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J. Clin. Psychiatry Mar 2010, 71(3):270-279.
33. Khan A., Faucett J., Lichtenberg P., Kirsch I., Brown W.A. A systematic review of comparative efficacy of treatments and controls for depression. PLoS One 2012, 7(7):e41778.
34. Moncrieff J., Cohen D. Rethinking models of psychotropic drug action. Psychother. Psychosom. 2005, 74(3):145-153.
35. Forkmann T., Scherer A., Boecker M., Pawelzik M., Jostes R., Gauggel S. The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome. BMC Psychiatry 2011, 11:83.
36. Cuijpers P., Turner E.H., Koole S.L., van Dijke A., Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depress. Anxiety May 2014, 31(5):374-378.
37. McHugh R.K., Whitton S.W., Peckham A.D., Welge J.A., Otto M.W. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J. Clin. Psychiatry Jun 2013, 74(6):595-602.
38. Andrews P.W., Thomson J.A., Amstadter A., Neale M.C. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front. Psychol. 2012, 3:117.